Диссертация (1140170), страница 17
Текст из файла (страница 17)
The potential for QT prolongation and proarrhythmia by nonantiarrhythmic drugs: clinical and regulatory implications. Report on a policyconference of the European Society of Cardiology. Eur Heart J. 2000;21:1216–31.105. Hayashi, Y., Ikeda, U., Hashimoto, T., Watanabe, T., Mitsuhashi, T. andShimada, K. (1999) Torsades de pointes ventricular tachycardia induced byclarithromycin and disopyramide in the presence of hypokalemia.
Pacing ClinElectrophysiol 22: 672-674.106. Hensey, C. and Keane, D. (2008) Clarithromycin induced torsade depointes. Irish J Med Sci 177: 67-68.107. Herxheimer A, Healy D. Arrythmias and sudden death in patients takingantipsychotic drugs.// BMI 2002; 325:12531254.108. Hofman N., Wilde A.A.M., Kaab S., et al.
Diagnostic criteria forcongenital long QT syndrome in the era of molecular genetics: do we need a scoringsystem? Eur Heart J. 2007;28(5):575–80.109. Hollister AS, Haverstock D, Choudri S. Moxifloxacin has a favorablecardiovascular safety profile in patients taking concomitant QTc prolonging drugs[abstr]. In: Program and abstracts of the 40th Interscience Conference on AntimicrobialAgents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000.Washington, DC: American Society for Microbiology, 2000:476.110. Hondeghem LM,Dujardin K,Hoffmann P,Dumotier B,De Clerck F.Druginduced QTC prolongation dangerously underestimates proarrhythmic potential:lessonsfrom terfenadine.J Cardiovasc Pharmacol 2011;57:589–97.111.
Honig PK, Wortham DC, Zamani K, Conner DP, Mulin JC, Cantilena LR.Terfenadine-ketoconazoleinteraction.Pharmacokineticconsequences. JAMA 1993;269:1513-8.118andelectrocardiographic112. Huang B.H., Wu C.H., Hsia C.P., Yin Chen C. Azithromycin-inducedtorsade de pointes. Pacing Clin Electrophysiol. 2007; 30(12): 1579-82.113. Iannini P Prolongation of QT interval is probably a class effect offluoroquinolones. BMJ 2001;322:46.114. Iannini PB, Circiumaru I, Byazrova E, Doddamani S, Kramer H.
QTcprolongation associated with levofloxacin [abstr]. In: Program and abstracts of the 40thInterscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario,Canada, September 17-20, 2000. Washington, DC: American Society for Microbiology,2000:47.115. Iannini PB, von Seggern K, Wikler MA. Safety of gatifloxacin in patientswith cardiovascular disease [abstr]. In: Program and abstracts of the 40th InterscienceConference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada,September 17-20, 2000.
Washington, DC: American Society for Microbiology,2000:469.116. Isbister G. K., Page C. B. Drug induced QT prolongation: the measurementand assessment of the QT interval in clinical practice //British journal of clinicalpharmacology. – 2013. – Т. 76. – №. 1. – С. 48-57.117. JaillonP,MorganrothJ,BrumptI,TalbotG.Overviewofelectrocardiographic and cardiovascular safety data for sparfloxacin.
J AntimicrobChemother 1996;37(suppl A):161-7.118. Janssen Pharmaceutica stops marketing cisapride in the US. FDA TalkPaper March 23, 2000.119. January C.T., Gong Q., Zhou Z. Long QT syndrome: cellular basis andarrhythmia mechanism in LQT2. J Cardiovasc Electrophysiol 2000 Dec; 11(12): 14131418.120. Jervell A., Lange-Nielsen F. Congenital deafmutism, functional heartdisease with prolongation of the QT interval and sudden death. Amer Heart J 1957; 54:59-68.119121. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE.Mechanisms, risk factors, and management of acquired long QT syndrome: acomprehensive review.
Scientific World Journal. 2012;2012:212178.122. Kamei S, Sato N, Harayama Y, Nunotani M, Takatsu K, Shiozaki T, et al.Molecular analysis of potassium ion channel genes in sudden death cases amongpatients administered psychotropic drug therapy: are polymorphisms in LQT genes apotential risk factor? J Hum Genet. 2014;59(2):95–9.123. Kamochi, H., Nii, T., Eguchi, K., Mori, T., Yamamoto, A., Shimoda, K.
etal. (1999) Clarithromycin associated with torsades de pointes. Japan Circulat J 63: 421422.124. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome.Pharmacol Rev. 2010;62(4):760–81.125. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes:recent advances. Curr Opin Cardiol. 2007;22(1):39–43.126. Kao L.W., Furbee R.B. Drug-induced q-T prolongation. Med. Clin.
North.Am. 2005; 89 (6): 1125–44, x127. Keating M., Atkinson D., Dunn C., et al. Linkage of a cardiac arrhythmia,the long QT syndrome, and the Harvey ras-1 gene. Science. 1991;252:704–6.128. Kezerashvili A., Khattak H., Barsky A., Nazari R., Fisher J.D.Azithromycin as a cause of QT-interval prolongation and torsade de pointes in theabsence of other known precipitating factors. J Interv Card Electrophysiol.
2007; 18(3):243-6.129. Kim J.A., Lopes C.M., Moss A.J. et al. Trigger-specific risk factors andresponse to therapy in long QT syndrome type 2. Heart Rhythm. Dec 2010;7(12):1797805.130. Kunkler K. Acquired long QT syndrome: risk assessment, prudentprescribing and monitoring, and patient education.
J Am Acad Nurse Pract.2002;14:382–9.120131. Lawrence KR, Nasraway SA. Conduction disturbances associated withadministration of butyrophenone antipsychotics in the critically ill: a review of theliterature. Pharmacotherapy 1997;17:531-7.132. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and theclinical implications.
Clin Pharmacokinet. 1998;35:361–90.133. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet1997;349:1322.134. Lopera J., Huikiri H.V., Makikallio T.H. Ischemic sudden death: criticalanalysis of risk markers. Part VIII Rev Esp Cardiol 2000 Apr;53(4):568-578.135. Mahida S, Hogarth AJ, Cowan C, Tayebjee MH, Graham LN, Pepper CB.Genetics of congenital and drug-induced long QT syndromes: current evidence andfuture research perspectives.
J Interv Card Electrophysiol. 2013;37(1):9–19.136. MalikM,CammAJ.Evaluationofdrug-inducedQTintervalprolongation:implications for drug approval and labelling. Drug Saf 2001; 24:323–51.137. Medeiros A., Kaku T., Tester D.J., et al. Sodium channel B4 subunitmutation causes congenital long QT-syndrome. Heart Rhythm.
2006;3:S34.138. Michalets EL, Williams CR. Drug interactions with cisapride: clinicalimplications. Clin Pharmacokinet 2000;39:49-75.139. Milberg, P., Eckardt, L., Bruns, H., Biertz, J., Ramtin, S., Reinsch, N. et al.(2002) Divergent proarrhythmic potential of macrolide antibiotics despite similar QTprolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsadede pointes.
J Pharmacol Exp Therapeut 303: 218-225.140. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on theelectrocardiogram. Chest 1999; 115:983-6.141. Mizusawa Y, Wilde A. A. M. QT Prolongation and Mortality in HospitalSettings: Identifying Patients at High Risk. Mayo Clin Proc 2013;88(4):309-1 1142. Mohler P.J., Le Scouarnec S., Denjoy I. et al.
Defining the cellularphenotype of ankyrin-B syndrome variants: human ANK2 variants associated with121clinical phenotypes display a spectrum of activities in cardiomyocytes // Circulation. 2007. - Vol. 115. - P. 432-441.143. Morganroth J, Talbot GH, Dorr MB, Johnson RD, Geary W, Magner D.Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiacrepolarization (QTc interval). Clin Ther 1999;21:818-28.144. Moric-Janiszewska E., Markiewicz-Loskot G.
et al. Challenges ofdiagnosisoflong-QTsyndromeinchildren.PacingClin.Electrophysiol.,2007;30(9):1168-1170.145. Moss A.J., Zareba W., Hall W.J. et al. Effectiveness and limitations ofbeta-blocker therapy in congenital long-QT syndrome. Circulation. 2000; 101 (6): 616–23.146. Moss AJ. The QT interval and torsade de pointes. Drug Saf 1999;21(suppl1):5-10, 81-7.147. Napolitano C., Priori S.G., Schwartz P.J. et al. Genetic testing in the longQT syndrome: development and validation of an efficient approach to genotyping inclinical practice // JAMA. - 2005.
- Vol. 294. - P. 2975-2980.148. Napolitano C., Schwartz P.J., Brown A.M. et al. Evidence for a cardiac ionchannel mutation underlying drug-induced QT prolongation and life-threateningarrhythmias. J Cardiovasc Electrophysiol 2000 Jun; 11(6): 691-696.149. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-inducedlongQTsyndrome:concordancewithquinidineandunderlyingcellularelectrophysiologic mechanism. Am J Med 1990;89:235-8.150. Novartis Gives Mellaril Black Box Warning to Alert MDs of ArrhythmiaRisk. Reuters Health Jul 26, 2000.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
